Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

✍ Scribed by Shivaani Kummar; Martin E. Gutierrez; Erin R. Gardner; Xiaohong Chen; William D. Figg; Maria Zajac-Kaye; Min Chen; Seth M. Steinberg; Christine A. Muir; Mary Ann Yancey; Yvonne R. Horneffer; Lamin Juwara; Giovanni Melillo; S. Percy Ivy; Maria Merino; Len Neckers; Patricia S. Steeg; Barbara A. Conley; Giuseppe Giaccone; James H. Doroshow; Anthony J. Murgo

• Book ID: 116430213
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 214 KB
• Volume: 46
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/j.ejca.2009.10.026